Abivax SA
ABVX105.270USD
+1.370+1.32%
收盤 11/07, 16:00（美東）報價延遲15分鐘
0.00總市值
--本益比TTM
關於 Abivax SA 公司
Abivax SA 是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化抗病毒化合物和治療性疫苗，以對抗嚴重和危及生命的傳染病。ABIVAX 利用 RNA-蛋白質相互作用干擾和細胞毒性 TH1 細胞擴增來產生療法，幫助患者清除 HIV、HBV 和 HPV 等病毒。該公司的產品線包括 ABX 203，這是從古巴遺傳工程和生物技術中心 (CIGB) 獲得的治療性疫苗候選藥物，適用於患有慢性乙型肝炎的患者；以及 ABX196，治療性疫苗的佐劑等。
Abivax SA簡介
公司代碼ABVX
公司名稱Abivax SA
上市日期Jun 26, 2015
CEOMr. Marc De Garidel
員工數量- -
證券類型Ordinary Share
年結日- -
公司地址7-11 Boulevard Haussmann
城市PARIS
上市交易所Euronext Paris
國家France
郵編75009
電話33153830963
網址https://www.abivax.com/
公司代碼ABVX
上市日期Jun 26, 2015
CEOMr. Marc De Garidel
Abivax SA公司高管
名稱
名稱/職務
職務
持股
持股變動
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mary Mantock
Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Mr. Patrick Malloy
Mr. Patrick Malloy
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 11月8日 週六
更新時間: 11月8日 週六
持股股東
股東類型
持股股東
持股股東
佔比
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.73%
Adar1 Capital Management LLC
4.17%
Cormorant Asset Management, LP
2.90%
Caligan Partners, LP
2.28%
其他
77.69%
持股股東
持股股東
佔比
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.73%
Adar1 Capital Management LLC
4.17%
Cormorant Asset Management, LP
2.90%
Caligan Partners, LP
2.28%
其他
77.69%
股東類型
持股股東
佔比
Hedge Fund
24.85%
Investment Advisor
12.52%
Investment Advisor/Hedge Fund
6.12%
Venture Capital
1.86%
Research Firm
0.89%
其他
53.77%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
120
34.39M
46.74%
-4.46M
2025Q2
74
31.84M
43.27%
-317.11K
2025Q1
74
31.82M
50.18%
-39.44K
2024Q4
67
29.91M
47.53%
+1.67M
2024Q3
53
27.43M
43.59%
-1.47M
2024Q2
50
28.12M
44.69%
-980.96K
2024Q1
45
23.37M
37.15%
+1.78M
2023Q4
32
21.64M
34.39%
+20.54M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
TCG Crossover Management, LLC
6.06M
8.23%
--
--
Jun 30, 2025
Deep Track Capital LP
3.48M
4.73%
-99.06K
-2.77%
Jun 30, 2025
Adar1 Capital Management LLC
3.07M
4.17%
+861.32K
+38.97%
Jun 30, 2025
Cormorant Asset Management, LP
2.13M
2.9%
--
--
Jun 30, 2025
Caligan Partners, LP
1.67M
2.28%
+405.28K
+31.93%
Jun 30, 2025
Nantahala Capital Management, LLC
1.48M
2.02%
--
--
Jun 30, 2025
Franklin Advisers, Inc.
1.37M
1.86%
--
--
Jun 30, 2025
VR Adviser, LLC
1.35M
1.83%
--
--
Jun 30, 2025
Great Point Partners, LLC
1.29M
1.76%
-346.49K
-21.15%
Jun 30, 2025
Octagon Capital Advisors LP
1.27M
1.72%
+37.00K
+3.01%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Simplify Health Care ETF
4.12%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
0%
Simplify Health Care ETF
佔比4.12%
Fidelity Nasdaq Composite Index ETF
佔比0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
佔比0%
Innovator IBD Breakout Opportunities ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
